Adelson 2005 HYPO 1.
Methods | Randomised controlled trial, parallel group | |
Participants |
Total number of participants: 48 Baseline characteristics: Therapeutic cooling Age: mean (SD) 6.92 (± 3.09) years Type of injury (closed/open): closed GCS on admission: mean (SD) 5.74 (± 1.39) No cooling Age: mean (SD) 6.86 (± 3.81) years Type of injury (closed/open): closed GCS on admission: mean (SD) 5.64 (± 1.63) Inclusion criteria: children 0 to 156 months of age, with non‐penetrating head injury, GCS ≤ 8, motor score < 6 Exclusion criteria: normal initial CT scan, extended hypotension for > 15 minutes, coagulopathy admission > 6 hours after injury, brain death on initial examination Country: USA Setting: hospital. 6 medical centres |
|
Interventions |
Therapeutic cooling Number of participants randomised: 23 Method of cooling: surface cooling using a hypothermia/heating blanket. Sedation and paralysis induced to prevent shivering Target temperature: 32 to 33 °C Time of cooling: < 6 hours Duration of cooling: 48 hours Rewarming details: after 48 hours, passive warming, 1 °C every 3 to 4 hours until 36.5 °C reached. Initiation of warming not stopped due to intracranial hypotension but slowed at times due to elevations in ICP Site of temperature measurement: rectal No cooling Number of participants: 25 Method of temperature management: participants were passively warmed if their initial presenting core temperature was < 36 °C Target temperature: 36.5 to 37.5 °C |
|
Outcomes | Outcomes measured in study: mortality, ventricular arrhythmias, delayed intracranial haemorrhage, intra‐abdominal/thoracic bleeding, coagulopathy infection (pneumonia), GOS (at 3 and 6 months), age‐appropriate neurocognitive tests, intracranial pressure, other secondary clinical outcomes | |
Notes |
Funding/declarations of interest: National Institute of Health grant, General Clinical Research Centre at Children's Hospital of Pittsburgh grant Study dates: July 1999 to December 2003 Note: study authors reported GOS at 3 months as "no difference between treatment groups" with P = 0.799; and GOS at 6 months with P = 0.540 |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Described as randomised and stratification done by age of child at time of injury. No additional details |
Allocation concealment (selection bias) | Unclear risk | Insufficient details provided |
Blinding of participants and personnel (performance bias): mortality | Low risk | Not possible to blind personnel; unlikely to influence performance |
Blinding of participants and personnel (performance bias): GOS | Unclear risk | Not possible to blind personnel; unclear if this would influence performance |
Blinding of participants and personnel (performance bias): pneumonia | Unclear risk | Not possible to blind personnel; unclear if this would influence performance |
Blinding of outcome assessment (detection bias): mortality; pneumonia | Low risk | Lack of blinding unlikely to influence outcome assessment |
Blinding of outcome assessment (detection bias): GOS | Low risk | Neurocognitive tests were performed by the site neuropsychologist or technician who were blinded to the therapeutic intervention |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Low for mortality and pneumonia. Small loss of follow‐up at 3 and 6 months for GOS data, although not reported by treatment groups |
Selective reporting (reporting bias) | Unclear risk | Clinical trials registration or pre‐published protocol not reported. Insufficient information to make judgement |
Other bias | Low risk | No other sources of bias identified |